Shares of Horizon rose nearly 3% in premarket trading Friday. Amgen's stock edged up slightly.Amgen first moved to buy Horizon in December 2022 in an effort to gain access to the latter's rare disease assets, including the thyroid eye disease therapy Tepezza.
In its lawsuit, the FTC said that the deal would allow Amgen to "entrench the monopoly positions" of Horizon's fast-growing medications, including Tepezza, and Krystexxa, a gout medicine.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: